Abstract
There is a critical need for the development of novel diagnostic and therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), a devastating disease known for its poor prognosis due to its late presentation and high aggressiveness. MicroRNAs (miRNAs) are a class of short non-coding RNAs that have been implicated in the gene regulation in normal cellular processes as well as cancer pathogenesis. Patterns of miRNA upregulation and downregulation have been found to be unique to specific cancers, including PDAC. MiRNA expression profiling may serve as a new strategy for the diagnosis and prognosis of PDAC cases. In addition, the role of miRNAs in important cellular processes such as cell development, survival, and proliferation may also be utilized for novel therapeutic approaches. This article presents current progress on the role of miRNAs as a biomarker and therapeutic target for PDAC.
Keywords: MicroRNA, pancreatic adenocarcinoma, prognosis, pathogenesis, oncogenic, ultrasound, formalin, metastasis, intratumoral, 2’-Omethoxethyl
Current Signal Transduction Therapy
Title:MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks
Volume: 7 Issue: 3
Author(s): Wei Li, Kei Satoh, Drake G. LeBrun and Min Li
Affiliation:
Keywords: MicroRNA, pancreatic adenocarcinoma, prognosis, pathogenesis, oncogenic, ultrasound, formalin, metastasis, intratumoral, 2’-Omethoxethyl
Abstract: There is a critical need for the development of novel diagnostic and therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), a devastating disease known for its poor prognosis due to its late presentation and high aggressiveness. MicroRNAs (miRNAs) are a class of short non-coding RNAs that have been implicated in the gene regulation in normal cellular processes as well as cancer pathogenesis. Patterns of miRNA upregulation and downregulation have been found to be unique to specific cancers, including PDAC. MiRNA expression profiling may serve as a new strategy for the diagnosis and prognosis of PDAC cases. In addition, the role of miRNAs in important cellular processes such as cell development, survival, and proliferation may also be utilized for novel therapeutic approaches. This article presents current progress on the role of miRNAs as a biomarker and therapeutic target for PDAC.
Export Options
About this article
Cite this article as:
Li Wei, Satoh Kei, G. LeBrun Drake and Li Min, MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481529
DOI https://dx.doi.org/10.2174/157436212802481529 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Recent Developments in the Virology and Antiviral Research of Severe Acute Respiratory Syndrome Coronavirus
Infectious Disorders - Drug Targets The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets
Current Molecular Medicine Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Sirtuins: Nodes Connecting Aging, Metabolism and Tumorigenesis
Current Pharmaceutical Design Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia
Current Drug Targets Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design